vs
Amphastar Pharmaceuticals, Inc.（AMPH）とApple Hospitality REIT, Inc.（APLE）の財務データ比較。上の社名をクリックして会社を切り替えられます
Apple Hospitality REIT, Inc.の直近四半期売上が大きい（$326.4M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.8倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 9.1%、差は4.3%）。Amphastar Pharmaceuticals, Inc.の前年同期比売上増加率が高い（-1.8% vs -2.0%）。Apple Hospitality REIT, Inc.の直近四半期フリーキャッシュフローが多い（$282.0M vs $24.6M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs -0.5%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
ライマン・ホスピタリティ・プロパティーズはホテル、リゾート、エンターテイメント、メディア事業を展開する企業で、テネシー州ナッシュビルに所在する国指定歴史的ランドマークのライマン礼拝堂を資産の一つとし、その名前の由来にもなっています。1983年にWSM社を買収しグランドオールオプリなどのIPを取得したことで、現在の事業の基盤が形成されました。
AMPH vs APLE — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $326.4M |
| 純利益 | $24.4M | $29.6M |
| 粗利率 | 46.8% | 37.2% |
| 営業利益率 | 19.4% | 15.2% |
| 純利益率 | 13.3% | 9.1% |
| 売上前年比 | -1.8% | -2.0% |
| 純利益前年比 | -35.7% | -0.7% |
| EPS（希薄化後） | $0.51 | $0.13 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $326.4M | ||
| Q3 25 | $191.8M | $373.9M | ||
| Q2 25 | $174.4M | $384.4M | ||
| Q1 25 | $170.5M | $327.7M | ||
| Q4 24 | $186.5M | $333.0M | ||
| Q3 24 | $191.2M | $378.8M | ||
| Q2 24 | $182.4M | $390.1M | ||
| Q1 24 | $171.8M | $329.5M |
| Q4 25 | $24.4M | $29.6M | ||
| Q3 25 | $17.4M | $50.9M | ||
| Q2 25 | $31.0M | $63.6M | ||
| Q1 25 | $25.3M | $31.2M | ||
| Q4 24 | $38.0M | $29.8M | ||
| Q3 24 | $40.4M | $56.3M | ||
| Q2 24 | $37.9M | $73.9M | ||
| Q1 24 | $43.2M | $54.0M |
| Q4 25 | 46.8% | 37.2% | ||
| Q3 25 | 51.4% | 40.6% | ||
| Q2 25 | 49.6% | 42.6% | ||
| Q1 25 | 50.0% | 39.0% | ||
| Q4 24 | 46.5% | 38.6% | ||
| Q3 24 | 53.3% | 41.9% | ||
| Q2 24 | 52.2% | 44.6% | ||
| Q1 24 | 52.4% | 40.1% |
| Q4 25 | 19.4% | 15.2% | ||
| Q3 25 | 13.2% | 19.4% | ||
| Q2 25 | 24.2% | 22.1% | ||
| Q1 25 | 21.9% | 15.5% | ||
| Q4 24 | 24.2% | 15.0% | ||
| Q3 24 | 29.8% | 20.5% | ||
| Q2 24 | 30.3% | 24.0% | ||
| Q1 24 | 27.9% | 21.7% |
| Q4 25 | 13.3% | 9.1% | ||
| Q3 25 | 9.0% | 13.6% | ||
| Q2 25 | 17.8% | 16.6% | ||
| Q1 25 | 14.8% | 9.5% | ||
| Q4 24 | 20.4% | 9.0% | ||
| Q3 24 | 21.1% | 14.9% | ||
| Q2 24 | 20.8% | 19.0% | ||
| Q1 24 | 25.1% | 16.4% |
| Q4 25 | $0.51 | $0.13 | ||
| Q3 25 | $0.37 | $0.21 | ||
| Q2 25 | $0.64 | $0.27 | ||
| Q1 25 | $0.51 | $0.13 | ||
| Q4 24 | $0.74 | $0.13 | ||
| Q3 24 | $0.78 | $0.23 | ||
| Q2 24 | $0.73 | $0.31 | ||
| Q1 24 | $0.81 | $0.22 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $8.5M |
| 総負債低いほど良い | $608.7M | $1.5B |
| 株主資本純資産 | $788.8M | $3.1B |
| 総資産 | $1.6B | $4.9B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.49× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $8.5M | ||
| Q3 25 | $276.2M | $50.3M | ||
| Q2 25 | $231.8M | $7.9M | ||
| Q1 25 | $236.9M | $14.9M | ||
| Q4 24 | $221.6M | $10.3M | ||
| Q3 24 | $250.5M | $6.1M | ||
| Q2 24 | $217.8M | $7.2M | ||
| Q1 24 | $289.6M | $4.9M |
| Q4 25 | $608.7M | $1.5B | ||
| Q3 25 | $608.6M | $1.5B | ||
| Q2 25 | $607.7M | $1.5B | ||
| Q1 25 | $603.9M | $1.5B | ||
| Q4 24 | $601.6M | $1.5B | ||
| Q3 24 | $596.4M | $1.5B | ||
| Q2 24 | $586.9M | $1.5B | ||
| Q1 24 | $594.0M | $1.5B |
| Q4 25 | $788.8M | $3.1B | ||
| Q3 25 | $776.7M | $3.2B | ||
| Q2 25 | $757.5M | $3.2B | ||
| Q1 25 | $751.3M | $3.2B | ||
| Q4 24 | $732.3M | $3.3B | ||
| Q3 24 | $727.7M | $3.3B | ||
| Q2 24 | $713.3M | $3.3B | ||
| Q1 24 | $672.4M | $3.3B |
| Q4 25 | $1.6B | $4.9B | ||
| Q3 25 | $1.7B | $4.9B | ||
| Q2 25 | $1.6B | $4.9B | ||
| Q1 25 | $1.6B | $4.9B | ||
| Q4 24 | $1.6B | $5.0B | ||
| Q3 24 | $1.5B | $5.0B | ||
| Q2 24 | $1.5B | $5.1B | ||
| Q1 24 | $1.6B | $5.0B |
| Q4 25 | 0.77× | 0.49× | ||
| Q3 25 | 0.78× | 0.47× | ||
| Q2 25 | 0.80× | 0.48× | ||
| Q1 25 | 0.80× | 0.48× | ||
| Q4 24 | 0.82× | 0.45× | ||
| Q3 24 | 0.82× | 0.46× | ||
| Q2 24 | 0.82× | 0.46× | ||
| Q1 24 | 0.88× | 0.45× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $370.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $282.0M |
| FCFマージンFCF / 売上 | 13.4% | 86.4% |
| 設備投資強度設備投資 / 売上 | 4.5% | 27.0% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 12.50× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $516.8M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $370.2M | ||
| Q3 25 | $52.6M | $126.4M | ||
| Q2 25 | $35.6M | $108.8M | ||
| Q1 25 | $35.1M | $49.1M | ||
| Q4 24 | $29.0M | $405.4M | ||
| Q3 24 | $60.0M | $128.2M | ||
| Q2 24 | $69.1M | $127.3M | ||
| Q1 24 | $55.3M | $54.7M |
| Q4 25 | $24.6M | $282.0M | ||
| Q3 25 | $47.2M | $109.0M | ||
| Q2 25 | $25.0M | $96.2M | ||
| Q1 25 | $24.4M | $29.5M | ||
| Q4 24 | $16.6M | $327.1M | ||
| Q3 24 | $46.2M | $113.1M | ||
| Q2 24 | $63.1M | $115.0M | ||
| Q1 24 | $46.5M | $34.4M |
| Q4 25 | 13.4% | 86.4% | ||
| Q3 25 | 24.6% | 29.2% | ||
| Q2 25 | 14.3% | 25.0% | ||
| Q1 25 | 14.3% | 9.0% | ||
| Q4 24 | 8.9% | 98.2% | ||
| Q3 24 | 24.1% | 29.9% | ||
| Q2 24 | 34.6% | 29.5% | ||
| Q1 24 | 27.1% | 10.4% |
| Q4 25 | 4.5% | 27.0% | ||
| Q3 25 | 2.8% | 4.7% | ||
| Q2 25 | 6.1% | 3.3% | ||
| Q1 25 | 6.3% | 6.0% | ||
| Q4 24 | 6.7% | 23.5% | ||
| Q3 24 | 7.2% | 4.0% | ||
| Q2 24 | 3.3% | 3.2% | ||
| Q1 24 | 5.1% | 6.2% |
| Q4 25 | 1.35× | 12.50× | ||
| Q3 25 | 3.03× | 2.49× | ||
| Q2 25 | 1.15× | 1.71× | ||
| Q1 25 | 1.39× | 1.57× | ||
| Q4 24 | 0.76× | 13.59× | ||
| Q3 24 | 1.48× | 2.28× | ||
| Q2 24 | 1.82× | 1.72× | ||
| Q1 24 | 1.28× | 1.01× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
APLE
| Occupancy | $293.0M | 90% |
| Hotel Other | $17.2M | 5% |
| Food And Beverage | $16.3M | 5% |
